ERBB2 and breast carcinoma: These findings suggest trastuzumab-mediated cardiotoxicity could be associated with long-term marked impairment of cardiac function and may contribute to increased risk of late-occurring cardiovascular disease in survivors of HER2-positive breast cancer.